Target Name: TBCEL
NCBI ID: G219899
Review Report on TBCEL Target / Biomarker Content of Review Report on TBCEL Target / Biomarker
TBCEL
Other Name(s): Leucine-rich repeat-containing protein 35 | Catastrophin | TBCEL variant 2 | TBCEL_HUMAN | leucine-rich repeat-containing protein 35 | catastrophin | El | Tubulin folding cofactor E-like, transcript variant 1 | tubulin folding cofactor E like | E-like | tubulin-specific chaperone e-like | leucine rich repeat containing 35 | Tubulin-specific chaperone e-like | Tubulin folding cofactor E like, transcript variant 2 | TBCEL variant 1 | EL | LRRC35 | Leucine rich repeat containing 35 | Tubulin-specific chaperone cofactor E-like protein

TBCEL: A Potential Drug Target and Biomarker for Leucine-rich Repeat-Containing Proteins

Leucine-rich repeat-containing proteins (LRRCPs) are a family of transmembrane proteins that play a crucial role in various cellular processes, including cell signaling, protein-protein interactions, and intracellular signaling cascades. TBCEL, a unique LRRCP, has been identified as a potential drug target and biomarker for various diseases. In this article, we will provide an overview of TBCEL, its functions, and potential therapeutic applications.

Overview of TBCEL

TBCEL, also known as PRT1-TBCEL, is a 21-kDa protein that belongs to the TBCEL family of LRRCPs. It is expressed in various tissues, including brain, heart, liver, and pancreas, and functions as a negative regulator of the insulin/IGF-1 signaling pathway. TBCEL plays a crucial role in the regulation of glucose metabolism and has been implicated in the development and progression of type 2 diabetes.

Potential Drug Target

TBCEL is a potential drug target due to its unique structure and various cellular processes that it is involved in. One of the key features of TBCEL is its ability to interact with various signaling molecules, including insulin, IGF-1, and PDGF. These interactions make TBCEL a potential target for drugs that target modulation of insulin/IGF-1 signaling pathway. Additionally, TBCEL has been shown to play a role in the regulation of cell adhesion, which is a critical process in the development of cancer.

Biomarker Potential

TBCEL has also been identified as a potential biomarker for various diseases. The ability of TBCEL to interact with insulin and IGF-1 has led to its potential use as a diagnostic tool for type 2 diabetes. By measuring the levels of TBCEL in peripheral tissues, researchers can assess insulin sensitivity and determine the effectiveness of potential therapeutic interventions. Additionally, TBCEL has been shown to be involved in the regulation of cell proliferation, which is a critical process in the development of cancer. This suggests that TBCEL may be a useful biomarker for monitoring the effectiveness of anti-cancer therapies.

Expression and Regulation

TBCEL is highly expressed in various tissues and has been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and invasion. It is also involved in the regulation of protein-protein interactions and in the regulation of DNA replication. TBCEL is regulated by various signaling pathways, including TGF-灏?, NF-kappa-B, and PI3K/AKT.

Conclusion

In conclusion, TBCEL is a unique and promising protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and various cellular processes make it an attractive target for therapeutic intervention. Further research is needed to determine the full potential of TBCEL as a drug and to explore its potential as a biomarker for various diseases.

Protein Name: Tubulin Folding Cofactor E Like

Functions: Acts as a regulator of tubulin stability

The "TBCEL Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBCEL comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TBCK | TBILA | TBK1 | TBKBP1 | TBL1X | TBL1XR1 | TBL1Y | TBL2 | TBL3 | TBP | TBPL1 | TBPL2 | TBR1 | TBRG1 | TBRG4 | TBX1 | TBX10 | TBX15 | TBX18 | TBX18-AS1 | TBX19 | TBX2 | TBX20 | TBX21 | TBX22 | TBX3 | TBX4 | TBX5 | TBX5-AS1 | TBX6 | TBXA2R | TBXAS1 | TBXT | TC2N | TCAF1 | TCAF1P1 | TCAF2 | TCAIM | TCAM1P | TCAP | TCEA1 | TCEA1P2 | TCEA2 | TCEA3 | TCEAL1 | TCEAL2 | TCEAL3 | TCEAL4 | TCEAL5 | TCEAL6 | TCEAL7 | TCEAL8 | TCEAL9 | TCEANC | TCEANC2 | TCERG1 | TCERG1L | TCF12 | TCF12-DT | TCF15 | TCF19 | TCF20 | TCF21 | TCF23 | TCF24 | TCF25 | TCF3 | TCF4 | TCF7 | TCF7L1 | TCF7L2 | TCFL5 | TCHH | TCHHL1 | TCHP | TCIM | TCIRG1 | TCL1A | TCL1B | TCL6 | TCN1 | TCN2 | TCOF1 | TCP1 | TCP10L | TCP10L2 | TCP10L3 | TCP11 | TCP11L1 | TCP11L2 | TCP11X2 | TCTA | TCTE1 | TCTN1 | TCTN2 | TCTN3 | TDG | TDGF1 | TDGF1P3 | TDGP1